Your browser doesn't support javascript.
loading
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.
Meester, Eric J; de Blois, Erik; Krenning, Boudewijn J; van der Steen, Antonius F W; Norenberg, Jeff P; van Gaalen, Kim; Bernsen, Monique R; de Jong, Marion; van der Heiden, Kim.
Afiliación
  • Meester EJ; Department of Biomedical Engineering, Thorax Center, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • de Blois E; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Krenning BJ; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • van der Steen AFW; Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands.
  • Norenberg JP; Department of Biomedical Engineering, Thorax Center, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • van Gaalen K; Radiopharmaceutical Sciences, University of New Mexico, Albuquerque, NM, USA.
  • Bernsen MR; Department of Biomedical Engineering, Thorax Center, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • de Jong M; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • van der Heiden K; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
EJNMMI Res ; 11(1): 27, 2021 Mar 17.
Article en En | MEDLINE | ID: mdl-33730311
PURPOSE: Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo signals is often limited to plaque identification. We evaluated binding of some promising radioligands in an in vitro approach in atherosclerotic plaques with different phenotypes. METHODS: Tissue sections of carotid endarterectomy tissue were characterized as early plaque, fibro-calcific plaque, or phenotypically vulnerable plaque. In vitro binding assays for the radioligands [111In]In-DOTATATE; [111In]In-DOTA-JR11; [67Ga]Ga-Pentixafor; [111In]In-DANBIRT; and [111In]In-EC0800 were conducted, the expression of the radioligand targets was assessed via immunohistochemistry. Radioligand binding and expression of radioligand targets was investigated and compared. RESULTS: In sections characterized as vulnerable plaque, binding was highest for [111In]In-EC0800; followed by [111In]In-DANBIRT; [67Ga]Ga-Pentixafor; [111In]In-DOTA-JR11; and [111In]In-DOTATATE (0.064 ± 0.036; 0.052 ± 0.029; 0.011 ± 0.003; 0.0066 ± 0.0021; 0.00064 ± 0.00014 %Added activity/mm2, respectively). Binding of [111In]In-DANBIRT and [111In]In-EC0800 was highest across plaque phenotypes, binding of [111In]In-DOTA-JR11 and [67Ga]Ga-Pentixafor differed most between plaque phenotypes. Binding of [111In]In-DOTATATE was the lowest across plaque phenotypes. The areas positive for cells expressing the radioligand's target differed between plaque phenotypes for all targets, with lowest percentage area of expression in early plaque sections and highest in phenotypically vulnerable plaque sections. CONCLUSIONS: Radioligands targeting inflammatory cell markers showed different levels of binding in atherosclerotic plaques and among plaque phenotypes. Different radioligands might be used for plaque detection and discerning early from vulnerable plaque. [111In]In-EC0800 and [111In]In-DANBIRT appear most suitable for plaque detection, while [67Ga]Ga-Pentixafor and [111In]In-DOTA-JR11 might be best suited for differentiation between plaque phenotypes.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: EJNMMI Res Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: EJNMMI Res Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos